Hims & Hers rises as LillyDirect access expands Zepbound and Foundayo options
Hims & Hers shares rose after the company said its clinicians can now route prescriptions for Eli Lilly’s Zepbound and Foundayo to LillyDirect, expanding access to branded obesity drugs. The move follows its prior Novo Nordisk arrangement and comes as investors focus on the shift away from compounded GLP-1s toward FDA-approved products.
1) What’s moving the stock today
Hims & Hers Health (HIMS) traded higher Friday, April 24, 2026, after fresh attention on its expanding access to branded GLP-1 obesity treatments. The key catalyst is the company’s update that its providers can send prescriptions for Eli Lilly’s Zepbound (including vials and KwikPen) and the Foundayo pill directly to LillyDirect, broadening the set of FDA-approved weight-loss drugs available through the Hims platform.
2) Why this matters now
The market is rewarding signs that Hims can keep growing its weight-loss business while pivoting away from compounded GLP-1s amid tightening U.S. oversight. By pointing consumers toward manufacturer-supported, cash-pay channels (LillyDirect) and combining that with its earlier branded GLP-1 availability via Novo Nordisk, Hims is positioning itself as a front-end demand generator and care/navigation layer in a rapidly evolving obesity-drug distribution model.
3) Key numbers and near-term watch items
Hims has highlighted consumer pricing for these options, including Foundayo starting at $149 per month and Zepbound starting at $299, plus a separate weight-loss membership fee structure. Investors will be watching whether the broader branded lineup improves conversion and retention without compressing unit economics, and whether the company can defend its position as manufacturers push direct-to-consumer models and intensify price competition.